title: Current landscape for treatment of advanced basal cell carcinoma.
abstract: Basal cell carcinomas (BCCs) account for around 80% of non-melanoma skin cancer. Australia has the highest incidence of BCC globally and the rates continue to increase in both Australia and New Zealand. BCC causes significant morbidity, placing an enormous burden on the healthcare system. Treatment of patients with advanced BCC can be particularly challenging. A panel of UK experts recently defined advanced disease as BCC that in which current treatment modalities are considered potentially contraindicated by clinical or patient-driven factors. Research has found that mutations in the hedgehog signalling pathway underpin the pathogenesis of the vast majority of sporadic BCC, as well as Gorlin syndrome. The first-in-class oral small molecule hedgehog pathway inhibitor - vismodegib-is now approved in a number of countries for use in locally-advanced and metastatic BCC and has resulted in improved outcomes in the majority of patients treated. With a number of similar agents in the pipeline, research is now focusing on identifying mechanisms that may contribute to resistance to this agent in some lesions.
authors.affiliation: Skin & Cancer Foundation Inc, Carlton, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia; St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Foley
mesh_terms: D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000556:secondary / Q000628:therapy*; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines
keywords: advanced; basal cell carcinoma; hedgehog; vismodegib